TMEM209 Inhibitors
TMEM209 inhibitors represent a class of chemical compounds specifically designed to reduce the functional activity of the transmembrane protein 209 (TMEM209). As a member of the transmembrane protein family, TMEM209 is involved in various cellular processes, including the regulation of metal ion transport, particularly iron. Inhibitors in this class are tailored to interfere with the normal function of TMEM209, which can be pivotal in maintaining cellular iron homeostasis. The mechanism of action for these inhibitors typically involves binding to the protein or altering its conformation in such a way that it impedes the protein's ability to interact with its natural substrates or partner proteins within the cellular membrane. By doing so, the inhibitors directly obstruct the transmembrane transport activity of TMEM209, leading to a downstream effect of modulating iron levels within the cell. Considering the role of iron in cellular metabolism and its importance in various enzymatic reactions, the inhibition of TMEM209 can have significant impacts on intracellular processes that are iron-dependent.
The specificity of TMEM209 inhibitors is crucial, as they are designed to target the protein without affecting other transmembrane proteins with similar functions or structures. This specificity is achieved through the precise molecular design that allows these inhibitors to differentiate TMEM209 from other proteins within the cellular membrane landscape. The interaction between TMEM209 inhibitors and the protein can be competitive, where the inhibitor competes with the natural substrate for binding sites, or non-competitive, where the inhibitor binds to a different site on the protein, causing a change in its activity without directly blocking the substrate binding. Through these interactions, TMEM209 inhibitors can effectively decrease the translocation of iron and other related ions across the cell membrane, thereby indirectly affecting cellular pathways that are reliant on these metal ions. Although the focus of TMEM209 inhibitors is not on applications, their role in understanding cellular iron transport and the regulation of metal ion homeostasis at the molecular level is of substantial interest in the field of biochemistry and cellular biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which leads to a reduction in AKT phosphorylation. Since TMEM209 has been implicated in the PI3K/AKT signaling pathway, LY294002 would inhibit TMEM209 activity by reducing AKT-mediated pathways that could stabilize TMEM209. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that blocks the mammalian target of rapamycin (mTOR) pathway. As mTOR is involved in protein synthesis and cell growth, its inhibition can decrease the synthesis and stability of TMEM209 through decreased translation and increased autophagic degradation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAP kinase. Inhibition of p38 MAPK can lead to decreased activation of downstream signaling components that may be involved in the regulation of TMEM209 stability or localization. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor, which prevents the activation of MAPK/ERK pathway. By inhibiting this pathway, PD98059 indirectly affects cellular processes that could be responsible for the modulation of TMEM209 levels or activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which may implicate in the control of cellular processes that stabilize or facilitate the activity of TMEM209. Inhibition of JNK activity can lead to altered transcriptional outcomes that decrease TMEM209 expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor like LY294002, but with a different binding mechanism. Wortmannin would lead to a reduction in AKT activation, thereby potentially decreasing cellular processes that stabilize TMEM209. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR tyrosine kinase inhibitor which may indirectly inhibit TMEM209 activity by limiting EGFR signaling pathways that could be involved in TMEM209 mediated processes. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Similar to Gefitinib, Erlotinib is also an EGFR inhibitor that would diminish EGFR mediated signaling pathways potentially involved in TMEM209 activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
A dual tyrosine kinase inhibitor that targets both EGFR and HER2/neu. By inhibiting these pathways, Lapatinib could indirectly affect TMEM209 activity by reducing signaling through these receptors that may be involved in TMEM209 stabilization. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
A RAF inhibitor which can also inhibit VEGFR and PDGFR. As these pathways can be involved in cellular processes affecting TMEM209, Sorafenib's action would lead to reduced TMEM209 activity through decreased signaling. | ||||||